Appco Pharma LLC Faces Nationwide Recall of Prazosin Hydrochloride Over Nitrosamine Impurity, Signaling Recurring cGMP Failures
Appco Pharma LLC has initiated a nationwide Class II recall of 58,896 bottles of Prazosin Hydrochloride Capsules, 2mg, due to N-nitroso-prazosin impurity C (NNP) exceeding acceptable limits. This cGMP deviation, impacting product manufactured for Biocon Pharma Inc., underscores Appco Pharma's recurring quality control challenges, necessitating immediate supply chain reassessment and diversification for procurement directors and regulatory affairs heads.
FDA Initiates Nationwide Recall of Appco Pharma's Prazosin Hydrochloride Due to Nitrosamine Impurity
The U.S. Food and Drug Administration (FDA) has announced a Class II, firm-initiated recall (D-0420-2026) of Prazosin Hydrochloride Capsules, USP, 2mg, manufactured by Appco Pharma LLC. This critical action, initiated on March 27, 2026, stems from a significant cGMP deviation: the detection of N-nitroso-prazosin impurity C (NNP) at levels exceeding acceptable regulatory limits. The affected product, distributed nationwide across the U.S.A., includes 58,896 bottles of 100-count capsules, specifically NDC 70377-067-11. The implicated lots are 2404153UC (Exp.: March 2026), 2404154UC (Exp.: March 2026), 2502055UC (Exp.: January 2027), 2505173UC (Exp.: May 2027), and 2505175UC (Exp.: May 2027). For procurement directors and supply chain VPs, this recall necessitates an immediate audit of existing inventory and distribution channels to identify and quarantine affected product. Regulatory affairs heads must ensure swift compliance with FDA guidelines for product withdrawal and patient notification, while business development executives should assess potential market shortages for Prazosin Hydrochloride, a molecule critical for managing hypertension and benign prostatic hyperplasia.
Appco Pharma LLC's Piscataway Facility Under Scrutiny for Quality Control
The Prazosin Hydrochloride Capsules subject to this recall were manufactured by Appco Pharma LLC at its facility in Piscataway, New Jersey, United States. This site, identified as a formulation manufacturing facility within the ChemLifeIntel Knowledge Graph, is a key production hub for the company's pharmaceutical offerings. While the specific FEI number for the Piscataway site is not disclosed in the available information, its role as the manufacturing origin for a product distributed nationwide underscores its significance in the U.S. pharmaceutical supply chain. Beyond Prazosin Hydrochloride, Appco Pharma LLC's product portfolio includes molecules such as Doxepin Hydrochloride and Clomiphene, indicating a broader manufacturing capability. For procurement and supply chain leaders, this event highlights the inherent risks associated with single-source reliance or inadequate oversight of contract manufacturing organizations. Any company currently sourcing active pharmaceutical ingredients (APIs) or finished dosage forms from Appco Pharma LLC should initiate a comprehensive risk assessment of all products originating from this Piscataway facility, evaluating potential exposure to similar cGMP deviations and nitrosamine contamination.
Supply Chain Exposure: Impact on Biocon Pharma Inc. and Prazosin Hydrochloride Market
This recall directly impacts Biocon Pharma Inc., Iselin, NJ, for whom the Prazosin Hydrochloride Capsules were manufactured. As the listed marketer, Biocon Pharma Inc. now faces significant supply chain disruption for this essential medication. Prazosin Hydrochloride, an alpha-1 blocker, is widely prescribed for the treatment of hypertension and symptoms of benign prostatic hyperplasia (BPH), placing this recall within the Genitourinary & Hormones therapeutic area. The withdrawal of 58,896 bottles from the U.S. market represents a tangible reduction in available supply, potentially leading to localized shortages or increased pricing pressure for remaining stock. Procurement directors at healthcare systems and wholesale distributors must immediately assess their current inventory of Prazosin Hydrochloride from all suppliers and anticipate potential gaps. Regulatory affairs teams at Biocon Pharma Inc. and its partners must navigate the complexities of product retrieval and communication with healthcare providers and patients. Business development executives should closely monitor market dynamics for Prazosin Hydrochloride, identifying opportunities for alternative suppliers to fill the emerging demand.
Strategic Sourcing: Identifying Alternative Suppliers for Prazosin Hydrochloride
Given the recall of Prazosin Hydrochloride Capsules from Appco Pharma LLC, procurement teams must urgently identify and qualify alternative suppliers to mitigate supply chain vulnerabilities. The ChemLifeIntel Knowledge Graph identifies several potential alternative manufacturers with established presences, offering opportunities for diversification. These include Advagen Pharma, Burel Pharmaceuticals, Qingdao Biopeptek, Alembic Pharmaceuticals, DARMERICA, and SCH Global Services. Notably, Ajanta Pharma, based in India, and Amneal Pharmaceuticals NY, located in the United States, represent geographically diverse options that could offer more resilient supply pathways. For procurement directors, initiating rapid due diligence and qualification processes with these alternative suppliers is paramount. This involves evaluating their regulatory compliance history, manufacturing capabilities, and capacity to meet demand for Prazosin Hydrochloride. While qualification timelines for new suppliers can be extensive, the urgency of this recall necessitates an accelerated approach, potentially leveraging existing audit reports or fast-tracking site visits. Prioritizing suppliers with a strong track record in nitrosamine risk management will be crucial to prevent future supply disruptions.
Appco Pharma LLC's Pattern of Recurring cGMP and Nitrosamine-Related Recalls
This latest recall of Prazosin Hydrochloride Capsules is not an isolated incident but rather indicative of a concerning pattern in Appco Pharma LLC's regulatory compliance history. The ChemLifeIntel Knowledge Graph reveals multiple prior Class II recalls stemming from significant quality control challenges. In January 2020, Appco Pharma faced an FDA Class II recall for its Ranitidine Capsules due to NDMA impurity and broader cGMP failures, marking an early instance of nitrosamine-related issues. More recently, in January 2025, the company initiated a recall for Venlafaxine, further signaling recurring quality control deficiencies. The current Prazosin Hydrochloride recall, again linked to a nitrosamine impurity (NNP) and cGMP deviation, reinforces a systemic issue rather than an isolated manufacturing error. This consistent history of recalls, particularly involving genotoxic impurities like nitrosamines, elevates Appco Pharma LLC to a higher risk profile for any company engaged in sourcing from them. Regulatory affairs professionals should anticipate increased FDA scrutiny on all products originating from Appco Pharma, while procurement teams must re-evaluate existing contracts and consider enhanced supplier auditing protocols to safeguard against future disruptions and reputational damage.
Remediation Requirements and Future Regulatory Outlook for Appco Pharma LLC
As a firm-initiated voluntary recall driven by a cGMP deviation, Appco Pharma LLC is now obligated to undertake a comprehensive remediation effort. This process will require a thorough root cause investigation into the formation of N-nitroso-prazosin impurity C (NNP) and the implementation of robust corrective and preventive actions (CAPA). The FDA will expect detailed documentation demonstrating how Appco Pharma plans to prevent recurrence, not only for Prazosin Hydrochloride but across its entire product portfolio, particularly given its history of nitrosamine-related recalls. For regulatory affairs teams, this implies a period of heightened oversight and potential for further FDA actions, including the issuance of a formal Warning Letter if the remediation efforts are deemed insufficient or untimely. Supply chain VPs should anticipate potential delays in product availability and consider the long-term viability of Appco Pharma as a reliable supplier. The company's ability to demonstrate sustained compliance and regain FDA confidence will dictate its future market access and reputation. Business development executives should prepare for a potentially protracted period of regulatory scrutiny, which could impact new product approvals and market expansion initiatives for Appco Pharma LLC.